Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial

ConclusionsPatients undergoing haemodialysis with moderate-to-severe CKD-aP receiving difelikefalin reported experiencing clinically meaningful improvements in both their pruritus symptoms and itch-related QoL.ClinicalTrials.gov registration number, NCT03998163; first submitted, 7 May 2019.

http://rd.springer.com/10.1007/s40271-023-00668-1

Source: The Patient - Patient-Centered Outcomes Research - January 9, 2024 Category: International Medicine & Public Health Source Type: research